SCHEMBL20053294

SCHEMBL20053294

CCOC(=O)N1CC(C(C)(C)CC)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.46
RECQL P46063 1/20 0.42
TSHR P16473 1/20 0.42
ALDH1A1 P00352 3/20 0.41
POLB P06746 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NOS3 P29474 1/20 0.41
NOS2 P35228 1/20 0.41
CHRM1 P11229 4/20 0.40
THRB P10828 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 3/20 0.37
PKM P14618 1/20 0.37
DPP4 P27487 1/20 0.36
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15298476 0.85 GAA (0.49) GAARECQLTSHRALDH1A1POLB
SCHEMBL20053362 0.79 SMN1; SMN2 (0.37) GAAALDH1A1SMN1; SMN2ATMKDM4E
SCHEMBL23100380 0.79 CHRNB2 (0.42) GAAALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL20053361 0.77 CHRNB2 (0.50) GAAALDH1A1SMN1; SMN2MAPT
SCHEMBL12384433 0.75 GAA (0.56) GAATSHRALDH1A1POLBHTT
SCHEMBL12083952 0.75 GAA (0.56) GAATSHRALDH1A1POLBHTT
SCHEMBL18307651 0.74 GAA (0.48) GAARECQLTSHRALDH1A1POLB
SCHEMBL14243070 0.74 CHRNB2 (0.51) GAARECQLTSHRALDH1A1POLB
SCHEMBL6509490 0.74 GAA (0.48) GAARECQLTSHRALDH1A1POLB
SCHEMBL15424547 0.74 GAA (0.48) GAARECQLTSHRALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10259818-B2 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors INCYTE CORPORATION (US) 2019-04-16 US disclosed
US-20190002470-A1 BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2019-01-03 US disclosed
US-9944646-B2 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors INCYTE HOLDINGS CORPORATION (US) 2018-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002470-A1 BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS PIK3CD, PIK3CA, PIK3CB GAA 1435/4885RECQL 2919/4885TSHR 3477/4885
US-10259818-B2 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors PIK3CD, PIK3CA, PIK3CB GAA 1435/4885RECQL 2919/4885TSHR 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.